The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane)-Reference-Cited by-同舟云学术

The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane)

Published:1990-03 Issue:3-4 Volume:29 Page:374-381
ISSN:0065-4299
Container-title:Agents and Actions
language:en
Short-container-title:Agents and Actions

Author:

Hasinoff B. B.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Toxicology,Pharmacology,Immunology

Link

http://link.springer.com/content/pdf/10.1007/BF01966470.pdf

Reference36 articles.

1. L. Gianni, B. J. Corden and C. E. Myers,The biochemical basis of anthracycline toxicity and antitumor activity. Reviews in Biochemical Toxicology5, 1–82 (1983).

2. B. Halliwell and J. M. C. Gutteridge,Free radicals in biology and medicine. Clarendon, Oxford 1985.

3. C. E. Myers, L. Gianna, C. B. Simone, R. Klecker and R. Greene,Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry21, 1707–1713 (1982).

4. J. Goodman and P. Hochstein.Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochem. Biophys. Res. Comm.77, 797–803 (1977).

5. E. G. Mimnaugh, M. A. Trush, M. Bhatnagar and T. E. Gram,Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem. Pharmacol.34, 847–856 (1985).

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Wrapping of Drug Assembly with Silica Layer and Confinement through Reversible Linkage with Copper(II) for Glutathione-responsive Nanocapsule;Chemistry Letters;2023-10-05

2. An In Vitro Comparison of the Effects of the Iron-Chelating Agents, CP94 and Dexrazoxane, on Protoporphyrin IX Accumulation for Photodynamic Therapy and/or Fluorescence Guided Resection;Photochemistry and Photobiology;2011-09-16

3. The use of cytoprotectants in the treatment of gynecological malignancies;The Women's Oncology Review;2007-01

4. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies;Cancer Chemotherapy and Pharmacology;2004-06-02

5. Radioprotectants: Current Status and New Directions;Oncology;2002